Size Exclusion Chromatography for Host Cell Protein Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The presence of high molecular weight aggregates and host cell proteins (HCPs) in biotherapeutic products poses challenges in drug development, manufacturing, and product stability, affecting efficacy and safety due to their potential to cause adverse immune responses and immunogenicity.
Innovation Solution
A method utilizing size exclusion chromatography (SEC) followed by liquid chromatography-mass spectrometry (LC-MS) for identifying, characterizing, and removing HCPs, involving optimized denaturation conditions, digestion, and surfactant use to separate and enrich HCPs from biotherapeutics, thereby improving the purity and safety of biotherapeutic products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional purification techniques (Protein A affinity chromatography) are used, then high-abundance therapeutic proteins are purified, but HCPs co-elute and cannot be effectively removed
Solution Approach 1:
The patent divides the complex mixture into separate size-based fractions using SEC, isolating HCP-containing fractions from the main therapeutic protein fraction. This segmentation enables targeted analysis and removal of HCPs without affecting the bulk therapeutic protein purification achieved by Protein A chromatography.
Solution Approach 2:
The patent introduces SEC as an intermediary separation technique between Protein A purification and final product formulation. This intermediate step uses size exclusion as a mediator to separate molecules based on hydrodynamic radius, allowing HCPs to be distinguished and removed from therapeutic proteins that co-eluted in the affinity chromatography step.
2Measurement precision
If direct LC-MS analysis is performed on crude samples with high-abundance therapeutic proteins, then therapeutic protein can be detected, but HCPs are masked and cannot be identified
Solution Approach 1:
The patent segments the sample into multiple SEC fractions before LC-MS analysis. By separating HCPs into distinct size-based fractions, the dynamic range problem is resolved - HCPs in low-abundance fractions can be detected without being masked by the overwhelming signal from high-abundance therapeutic proteins in the main fraction.
Solution Approach 2:
The patent adds a size-based separation dimension (SEC) before the mass spectrometry detection dimension. This creates a two-dimensional separation space where proteins are first separated by size, then analyzed by MS. This dimensional approach allows simultaneous detection of both high-abundance therapeutic proteins and low-abundance HCPs that would otherwise be indistinguishable in a single-dimensional MS analysis.
3Ease of manufacture
If HCPs are present in the final drug substance, then manufacturing is simplified, but product safety and quality are compromised
Solution Approach 1:
The patent performs preliminary SEC-based separation and HCP identification before final drug substance formulation. By proactively identifying and characterizing HCPs in early development stages using the SEC-LC-MS workflow, manufacturers can implement targeted removal strategies before scaling up production, ensuring safety without requiring complete redesign of the manufacturing process.
Solution Approach 2:
The patent implements a feedback mechanism where SEC-LC-MS analysis of HCPs in drug substance informs optimization of downstream purification processes. The identified HCP profiles and their size-based distribution provide feedback for adjusting chromatography conditions, adding selective removal steps, or modifying process parameters to eliminate specific HCPs while maintaining manufacturing efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables sensitive and specific identification and removal of HCPs, enhancing the stability and immunogenicity profile of biotherapeutic products by effectively separating and quantifying HCPs from therapeutic proteins, thereby improving product safety and efficacy.
Implementation Method 1
A method has been developed for identifying HCPs using size exclusion chromatography (SEC) as an orthogonal separation method prior to subjecting a sample including a protein of interest to liquid chromatography-mass spectrometry (LC-MS) analysis
Data Source
AI summary
The present invention generally pertains to methods of identifying and characterizing host cell proteins. In particular, the present invention pertains to the use of size exclusion chromatography in non-denaturing or denaturing conditions to enrich a sample for host cell proteins and characterize the binding of host cell proteins to a protein of interest.